Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Aspartic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.58 |
| ▸ | SLC1A3 | P43003 | 5/20 | 0.52 |
| ▸ | SLC1A2 | P43004 | 5/20 | 0.52 |
| ▸ | SLC1A1 | P43005 | 4/20 | 0.52 |
| ▸ | GRIK1 | P39086 | 9/20 | 0.50 |
| ▸ | GRIK2 | Q13002 | 5/20 | 0.50 |
| ▸ | GRIA4 | P48058 | 4/20 | 0.50 |
| ▸ | GRIK3 | Q13003 | 4/20 | 0.50 |
| ▸ | GRIK5 | Q16478 | 4/20 | 0.50 |
| ▸ | GRIA2 | P42262 | 3/20 | 0.50 |
| ▸ | GRIA1 | P42261 | 2/20 | 0.50 |
| ▸ | BHMT | Q93088 | 1/20 | 0.50 |
| ▸ | GRM1 | Q13255 | 2/20 | 0.48 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.48 |
| ▸ | GRM8 | O00222 | 1/20 | 0.46 |
| ▸ | GRM6 | O15303 | 1/20 | 0.46 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.46 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.46 |
| ▸ | GSR | P00390 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Aspartic Acid SCHEMBL464908 | 1.00 | SLC7A5 (0.58) | SLC7A5SLC1A3SLC1A2SLC1A1GRIK1 | |
| Aspartic Acid SCHEMBL23454434 | 1.00 | SLC7A5 (0.58) | SLC7A5SLC1A3SLC1A2SLC1A1GRIK1 | |
| Aspartic Acid SCHEMBL939864 | 1.00 | SLC7A5 (0.58) | SLC7A5SLC1A3SLC1A2SLC1A1GRIK1 | |
| Aspartic Acid SCHEMBL22092469 | 1.00 | SLC7A5 (0.58) | SLC7A5SLC1A3SLC1A2SLC1A1GRIK1 | |
| Aspartic Acid SCHEMBL14676938 | 0.95 | SLC7A5 (0.54) | SLC7A5SLC1A3SLC1A2SLC1A1GRIK1 | |
| Aspartic Acid SCHEMBL14676940 | 0.95 | SLC7A5 (0.54) | SLC7A5SLC1A3SLC1A2SLC1A1GRIK1 | |
| Aspartic Acid SCHEMBL1962483 | 0.93 | SLC7A5 (0.52) | SLC7A5SLC1A3SLC1A2SLC1A1GRIK1 | |
| Aspartic Acid SCHEMBL1962486 | 0.93 | SLC7A5 (0.52) | SLC7A5SLC1A3SLC1A2SLC1A1GRIK1 | |
| Aspartic Acid SCHEMBL8386686 | 0.92 | SLC7A5 (0.61) | SLC7A5SLC1A3SLC1A2SLC1A1GRIK1 | |
| Aspartic Acid SCHEMBL3442616 | 0.91 | SLC7A5 (0.50) | SLC7A5SLC1A3SLC1A2SLC1A1GRIK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 131 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10381112-B2 | Method and system for characterizing allergy-related conditions associated with microorganisms | uBiome, Inc. (US) | 2019-08-13 | — | — | US | claimed |
| US-10325071-B2 | Method and system for microbiome-derived diagnostics and therapeutics for neurological health issues | uBiome, Inc. (US) | 2019-06-18 | — | — | US | claimed |
| US-10268803-B2 | Method and system for microbiome-derived diagnostics and therapeutics for neurological health issues | uBiome, Inc. (US) | 2019-04-23 | — | — | US | claimed |
| US-20170277845-A1 | METHOD AND SYSTEM FOR MICROBIOME-DERIVED DIAGNOSTICS AND THERAPEUTICS FOR NEUROLOGICAL HEALTH ISSUES | uBiome, Inc. (US) | 2017-09-28 | — | — | US | claimed |
| US-20170277843-A1 | METHOD AND SYSTEM FOR MICROBIOME-DERIVED DIAGNOSTICS AND THERAPEUTICS FOR NEUROLOGICAL HEALTH ISSUES | uBiome, Inc. (US) | 2017-09-28 | — | — | US | claimed |
| US-9186394-B2 | Pharmacological vitreolysis | THROMBOGENICS NV (BE) | 2015-11-17 | — | — | US | claimed |
| US-8834869-B2 | Pharmacological vitreolysis | THROMBOGENICS NV (BE) | 2014-09-16 | — | — | US | claimed |
| US-20130302304-A1 | PHARMACOLOGICAL VITREOLYSIS | THROMBOGENICS NV (BE) | 2013-11-14 | — | — | US | claimed |
| US-20130202613-A1 | PHARMACOLOGICAL VITREOLYSIS | THROMBOGENICS NV (BE) | 2013-08-08 | — | — | US | claimed |
| US-20130195887-A1 | PHARMACOLOGICAL VITREOLYSIS | THROMBOGENICS NV (BE) | 2013-08-01 | — | — | US | claimed |
| US-20090081187-A1 | Liquefying a vitreous and/or inducing posterior vitreous detachment of an eye via microplasmin injection; treating vision defects; preventing or reducing the risk of retinal detachment; catalytic domain of plasmin | THROMB-X NV (BE) | 2009-03-26 | — | — | US | claimed |
| US-20090074739-A1 | non-surgical method for preventing or reducing the rate of the progression of non-proliferative diabetic retinopathy to the proliferative form ; treating vision defects; preventing or reducing the risk of retinal detachment; catalytic domain of plasmin | THROMB-X NV (BE) | 2009-03-19 | — | — | US | claimed |
| US-20080050356-A1 | Liquefying a vitreous and/or inducing posterior vitreous detachment of an eye via microplasmin injection; treating vision defects; preventing or reducing the risk of retinal detachment | THROMB-X NV (BE) | 2008-02-28 | — | — | US | claimed |
| EP-1292615-B1 | MODIFIED MORBILLIVIRUS V PROTEINS | WYETH CORP (US) | 2006-10-25 | — | — | EP | claimed |
| US-6664066-B2 | Mutant measles virus V protein; gene expression and engineering | WYETH HOLDINGS CORPORATION | 2003-12-16 | — | — | US | claimed |
| US-20030206925-A1 | MODIFIED MORBILLIVIRUS V PROTEINS | WYETH HOLDINGS CORPORATION | 2003-11-06 | — | — | US | claimed |
| US-6153407-A | NUCLEIC ACID WHICH CODES FOR ERYTHROPOIETIN BUT ALSO HAS UNTRANSLATED 5' OR 3' ENDS OF DEFINED SEQUENCE; FOR RECOMBINANT PRODUCTION OF PROTEIN WITH ALTERED BIOLOGICAL ACTIVITY | BETH ISRAEL DEACONESS MEDICAL CENTER (US) | 2000-11-28 | — | — | US | claimed |
| EP-0210257-A4 | PROTEIN WHICH IS CHARACTERISTIC OF RHEUMATOID ARTHRITIS. | HURWITZ CHARLES (US) | 1988-01-20 | — | — | EP | claimed |
| EP-0210257-A1 | PROTEIN WHICH IS CHARACTERISTIC OF RHEUMATOID ARTHRITIS | HURWITZ, Charles (US) | 1987-02-04 | — | — | EP | claimed |
| WO-1986004588-A1 | PROTEIN WHICH IS CHARACTERISTIC OF RHEUMATOID ARTHRITIS | HURWITZ CHARLES (US) | 1986-08-14 | — | — | WO | claimed |